Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2022 American Society of Cataract and Refractive Surgery Annual Meeting

SAN CLEMENTE, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its technologies will be featured in various scientific programming at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, being held April 22–26, 2022 in Washington, D.C.

In addition, Glaukos is sponsoring an educational symposium in conjunction with ASCRS and EyeWorld entitled “Expanding Your Treatment Algorithm: New, Innovative Product Portfolio from Glaukos” on Friday, April 22, 2022, at 5:30-6:30 p.m. ET in Salon GHI at the Walter E. Washington Convention Center. The faculty includes John Berdahl, MD (Moderator); Nicole Fram, MD; Nathan Radcliffe, MD; Mitchell Shultz, MD; and Blake Williamson, MD. Go here for more information and to register. Glaukos will also be exhibiting onsite at booth #1601.

Key Glaucoma Presentations:

• Jessica Cao, MD
  Three-Year Outcomes of Trabecular Micro-Bypass Stent between Glaucoma Severities

  Trabecular Micro-Bypass Stent Combined with Phacoemulsification in Primary Angle Closure Glaucoma

• Alexander J. DeWeerd
  Evaluating the Effect of Topical Medications on the Success of iStent inject^® with Cataract Surgery

• Aziza Dhalai
  Longitudinal Study of Two Second-Generation Trabecular Micro-Bypass Systems with Combined Cataract Surgery

• Zachary C. Dockter
  Trabecular Micro-Bypass Stent Implantation with Cataract Surgery in Open-Angle Glaucoma: Nine-Year Results

• Tanner J. Ferguson, MD
  Trabecular Micro-Bypass Stent Implantation with Cataract Extraction in Pseudoexfoliative Glaucoma: Long-Term Results

• Brian E. Flowers, MD
  Prospective Multicenter Pivotal Trial of a Three-Stent, Standalone Trabecular Micro-Bypass System for Open-Angle Glaucoma: One-Year Outcomes

• Benjamin L. Heller
  Medium- and Wide-Flange Trabecular Micro-Bypass Stent Implantation with Cataract Surgery in Primary Open-Angle Glaucoma: 18-Month Results

• Fritz H. Hengerer, MD
  Sustained Five-Year Glaucoma Control after Second-Generation Trabecular Micro-Bypass with or without Cataract Surgery

• Aiman N. Jamal
  Real-World Experience of Second-Generation Trabecular Micro-Bypass Stents - Outcomes at a Regional Ophthalmic Centre in the UK

• Jiaru Liu, MD
  Prospective Evaluation of the iStent inject in Conjunction with Phacoemulsification for Open-Angle Glaucoma: Efficacy and Safety

• Jesse McKey, MD
  IOP Reduction and Medication Elimination after Second-Generation Trabecular Micro-Bypass Stents with Cataract Surgery in U.S. Glaucoma Patients

• Mitchell C. Shultz, MD
  Effectiveness and Safety of Two Different Trabecular MIGS Devices in Patients with Mild-to-Moderate Glaucoma

  Second-Generation Trabecular Micro-Bypass +/- Ab Interno Canaloplasty to Potentiate Aqueous Outflow and Reduce Intraocular Pressure in Glaucoma

• John D. Stephens, MD
  Comparison of Two Different Trabecular MIGS Devices in Patients with Mild-to-Moderate Open-Angle Glaucoma

• Caroline W. Wilson, MD
  Implantation of Two Second-Generation Trabecular Micro-Bypass Stents with Cataract Surgery in Open-Angle Glaucoma: Three-Year Outcomes

Key Corneal Health Presentations:

• Kanika Agarwal, MD
  Outcomes of Precise Epithelium Removal for Ectatic Corneas Technique (PERFECT) in Corneal Collagen Cross-Linking (CXL)

• Miltiadis Balidis
  Two-Year Results of Transepithelial Oxygen Augmented Customized Cross-Linking for Keratoconus

• Brendan G. Cronin
  Oxygen-Enriched Transepithelial Corneal Cross-Linking with Pulsed and Accelerated Irradiation for Progressive Keratoconus: One-Year Results

• Eduardo da Costa
  Comparison of Scheimpflug-Based Metrics Post Corneal Collagen Cross-Linking and Intracorneal Ring Segments for Keratoconus

• Philip Dockery, MD
  Clinical Presentation of Progressive Keratoconus and Treatment Outcomes for Corneal Cross-Linking by Race

• Atanu Ghosh
  Corneal Biomechanical Changes in Progressive Keratoconus after Oxygen-Supplemented Transepithelial Accelerated Corneal Cross-Linking

• Subba R. Gollamudi, MD
  Corneal Swelling Induced by Hypotonic Riboflavin in Thin Keratoconus Corneas during Corneal Cross-Linking

• Eric Kim
  Corneal Cross-Linking for Progressive Keratoconus: A Retrospective Analysis of 514 Consecutive Eyes

• Suphi Taneri, MD
  Long-Term Safety and Efficacy of Pulsed-Light High-Fluence Accelerated Cross-Linking in Progressive Keratoconus Patients

• Julia Yu
  Corneal Collagen Cross-Linking Outcomes for Pediatric Keratoconus Patients in the United States

Abstracts and full session details can be found at www.ascrs.org.

The ASCRS Annual Meeting is among the largest gatherings of anterior segment physicians, medical personnel and industry executives in the ophthalmic industry. All educational content of the ASCRS Annual Meeting is planned by its program committee, and ASCRS does not endorse, promote, approve or recommend the use of any products, devices or services.

About Glaukos

Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012, and has since developed a portfolio of technologically distinct and leverageable platforms to support ongoing pharmaceutical and medical device innovations. Products or product candidates for each of these platforms are designed to advance the standard of care through better treatment options across the areas of glaucoma, corneal disorders and retinal diseases.

About iStent inject W Trabecular Micro-Bypass System (U.S.)

Indication for Use: The iStent inject W Trabecular Micro-Bypass System Model G2-W is indicated for use in conjunction with cataract surgery for the reduction of intraocular pressure (IOP) in adult patients with mild to moderate primary open-angle glaucoma.

Contraindications: The iStent inject W is contraindicated in eyes with angle-closure glaucoma, traumatic, malignant, uveitic, or neovascular glaucoma, discernible congenital anomalies of the anterior chamber (AC) angle, retrobulbar tumor, thyroid eye disease, or Sturge-Weber Syndrome or any other type of condition that may cause elevated episcleral venous pressure.

Warnings: Gonioscopy should be performed prior to surgery to exclude congenital anomalies of the angle, PAS, rubeosis, or conditions that would prohibit adequate visualization of the angle that could lead to improper placement of the stent and pose a hazard.

MRI Information: The iStent inject W is MR-Conditional, i.e., the device is safe for use in a specified MR environment under specified conditions; please see Directions for Use (DFU) label for details.

Precautions: The surgeon should monitor the patient postoperatively for proper maintenance of IOP. The safety and effectiveness of the iStent inject W have not been established as an alternative to the primary treatment of glaucoma with medications, in children, in eyes with significant prior trauma, abnormal anterior segment, chronic inflammation, prior glaucoma surgery (except SLT performed > 90 days preoperative), glaucoma associated with vascular disorders, pseudoexfoliative, pigmentary or other secondary open-angle glaucomas, pseudophakic eyes, phakic eyes without concomitant cataract surgery or with complicated cataract surgery, eyes with medicated IOP > 24 mmHg or unmedicated IOP < 21 mmHg or > 36 mmHg, or for implantation of more or less than two stents.

Adverse Events: Common postoperative adverse events reported in the iStent inject randomized pivotal trial included stent obstruction (6.2%), intraocular inflammation (5.7% for iStent inject vs. 4.2% for cataract surgery only), secondary surgical intervention (5.4% vs. 5.0%) and BCVA loss ≥ 2 lines ≥ 3 months (2.6% vs. 4.2%).

Caution: Federal law restricts this device to sale by, or on the order of, a physician. Please see DFU for a complete list of contraindications, warnings, precautions, and adverse events.

For more information, visit www.glaukos.com.

About Photrexa^® Viscous and Photrexa

Indications: Photrexa Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution) and Photrexa (riboflavin 5’-phosphate ophthalmic solution) are indicated for use with the KXL^® System in corneal collagen cross-linking for the treatment of progressive keratoconus and corneal ectasia following refractive surgery.

Important Safety Information: Corneal collagen cross-linking should not be performed on pregnant women. Ulcerative keratitis can occur. Patients should be monitored for resolution of epithelial defects. The most common ocular adverse reaction was corneal opacity (haze). Other ocular side effects include punctate keratitis, corneal striae, dry eye, corneal epithelium defect, eye pain, light sensitivity, reduced visual acuity and blurred vision. These are not all of the side effects of the corneal collagen cross-linking treatment.

For more information, go to www.livingwithkeratoconus.com/ to obtain the FDA-approved product labeling.

Photrexa Viscous and Photrexa are manufactured for Avedro. The KXL System is manufactured by Avedro. Avedro is a wholly owned subsidiary of Glaukos Corporation.

Forward-Looking Statements

All statements other than statements of historical facts included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. Although we believe that we have a reasonable basis for forward-looking statements contained herein, we caution you that they are based on current expectations about future events affecting us and are subject to risks, uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control, that may cause our actual results to differ materially from those expressed or implied by forward-looking statements in this press release. These potential risks and uncertainties include, without limitation, the timing and extent to which obtain regulatory approval for investigational products, our ability to successfully commercialize such products, the ability to obtain and maintain adequate financial coverage and reimbursement for our products, and the continued efficacy and safety profile of our products as might be suggested in the presentations at the ASCRS meeting. These and other risks, uncertainties and factors related to Glaukos, and our business are described in detail under the caption “Risk Factors” and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2021, which was filed with the Securities and Exchange Commission (SEC) on February 28, 2022. Our filings with the SEC are available in the Investor Section of our website at www.glaukos.com or at www.sec.gov. In addition, information about the risks and benefits of our products is available on our website at www.glaukos.com. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on the forward-looking statements in this press release, which speak only as of the date hereof. We do not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220421005291/en/